Is Compounded Semaglutide FDA Approved? The 2026 Rules Explained

No. Compounded semaglutide is not FDA approved, and it never was. That is not a technicality or a marketing nuance. In the FDA’s own words, compounded drugs “are not FDA approved,” which means “the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed” [1].

That was true in 2023 when compounded semaglutide was everywhere, and it is still true today. What has changed is the legal ground underneath it. Between February 2025 and mid-2026 the FDA closed the door that made mass-market compounded semaglutide possible, and started enforcing hard. This article explains what is actually allowed now, what the risks are, and what to ask before you hand over a credit card.

This is general information, not medical or legal advice. Decisions about any medicine belong with a licensed healthcare provider.

What does “compounded” actually mean?

Compounding is when a pharmacy makes a customized medicine for a patient, for example leaving out a dye someone is allergic to, or making a liquid version for a person who cannot swallow pills. It is a legitimate, long-standing part of pharmacy practice.

What it is not is generic manufacturing. A generic drug goes through an FDA application, must prove it performs the same way as the brand product, and is inspected as a manufactured drug. A compounded drug skips all of that. The FDA makes the point bluntly in its March 2026 enforcement announcement: “Compounded drugs are also not the same as generic drugs, which are FDA-approved” [4].

There are two kinds of compounder under federal law:

• 503A pharmacies. Traditional state-licensed pharmacies. They compound for an individual patient based on a prescription.
• 503B outsourcing facilities. Larger operations that can make batches without patient-specific prescriptions, register with the FDA and follow certain manufacturing standards.

Neither may normally make something that is “essentially a copy” of a commercially available FDA-approved drug.

Why was compounded semaglutide legal at all?

Because of the shortage exception. When an approved drug is on the FDA drug shortage list, the copy restriction relaxes. Semaglutide injection was on that list from 2022 until February 21, 2025 [2]. That three-year window is what created the compounded GLP-1 industry.

When the FDA resolved the shortage, it gave compounders a wind-down period [2]:

Who	Shortage-based enforcement discretion ended
503A pharmacies and physicians	April 22, 2025
503B outsourcing facilities	May 22, 2025

Compounders sued to stop it and lost, twice. A federal court in Texas denied a preliminary injunction in the semaglutide case on April 24, 2025, and in the parallel tirzepatide case held on May 7, 2025 that the FDA had acted within its authority [2][11]. On August 27, 2026 the US Court of Appeals for the Fifth Circuit affirmed in both cases, Nos. 25-10758 (semaglutide) and 25-10600 (tirzepatide), rejecting the Outsourcing Facilities Association’s Administrative Procedure Act arguments [13][14]. The decisions are unpublished, but they leave the FDA’s delisting in place and remove the main legal theory compounders had for reopening the shortage pathway.

The FDA’s own summary of where things stand is one sentence long: “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list” [2].

So is compounded semaglutide legal in 2026?

Only in narrow, patient-specific circumstances. The FDA’s guidance is that “compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug” [1].

In April 2026 the agency spelled out what counts as an unlawful copy. A compounded product is essentially a copy when it has the same active ingredient as a commercially available product at the same, similar or easily substitutable strength and can be given by the same route, unless the prescriber determines and documents a change that makes a significant difference for that individual patient [2].

Two details from that update are worth knowing because they shut down common workarounds:

1. Adding vitamin B12 does not make it a different drug. FDA gave semaglutide plus cyanocobalamin as its example, and said a combination can still be essentially a copy when both components are within 10% of the strengths of the commercially available products and the route is the same [2].
2. There is a small-volume threshold. FDA said it does not intend to act against a 503A compounder that fills “four or fewer prescriptions of that compounded drug product during a calendar month” [2]. That is a narrow enforcement policy, not a license for a telehealth pipeline.

Separately, the FDA says semaglutide salt forms cannot lawfully be compounded. Semaglutide sodium and semaglutide acetate “are different active ingredients than are used in the approved drugs,” FDA has no data on whether they behave the same way, and the agency is “not aware of any lawful basis for their use in compounding” [1].

And retatrutide and cagrilintide cannot be compounded at all. They are investigational, they are not components of any approved drug, and FDA has warned telehealth companies marketing retatrutide, active ingredient distributors selling it to compounders, and outsourcing facilities repackaging it [1].

Is compounded semaglutide safe?

The honest answer is that nobody can tell you, because nobody checks before it is sold. What we do have is the FDA’s running tally of problems.

Adverse events. As of May 31, 2026, FDA had received 990 reports of adverse events associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency notes that federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events, “so it is likely that adverse events from compounded versions of these drugs are underreported” [1].

Dosing errors. FDA has documented multiple adverse events, some requiring hospitalization, tied to dosing errors with compounded injectable semaglutide, from patients measuring their own doses out of vials and from clinicians miscalculating them [9]. It has also received reports of harm from prescribing at doses beyond the approved labeling, whether that means more drug per dose, more frequent doses, or faster titration [1].

Storage problems. Injectable GLP-1 drugs need refrigeration. FDA says it has received complaints of compounded products arriving warm or with inadequate ice packs, and advises not using any injectable GLP-1 that arrives that way [1].

Multi-dose vials. FDA recommends discarding a multi-dose vial within 28 days of first use even if medicine is left, and says explicitly not to follow compounder instructions that allow longer use [1]. Always use a new sterile needle and syringe for each dose.

Fraudulent labels. This one is genuinely alarming. FDA says it is aware of compounded semaglutide and tirzepatide in the United States “that contain false information on the product label,” including cases where “the compounding pharmacies identified on the labels of the products do not exist,” and other cases where a real licensed pharmacy’s name was used on a product it did not make [1].

Ingredient quality. In September 2025 FDA launched a “green list” of GLP-1 active ingredient manufacturers judged to be compliant with US manufacturing standards, and on September 19, 2025 issued Import Alert 66-80 so field staff can detain shipments from manufacturers not on that list [1][8]. Reporting on the program indicates FDA evaluated 48 GLP-1 API sites and found 21% noncompliant.

What has the FDA actually done about it?

A lot, and quickly, over the last twelve months:

• September 2025: more than 55 warning letters to online sellers of compounded GLP-1s, most dated September 9 and published through September 16, citing claims that compounded products were generic versions, had the same active ingredient, or were clinically proven [3].
• January 16, 2026: a warning letter to the 503A pharmacy Boothwyn Pharmacy citing insanitary conditions and products that did not match their stated strength, quality or purity.
• February 6, 2026: an FDA statement announcing intent to restrict GLP-1 active ingredients headed for mass-marketed compounded products, naming Hims & Hers, and warning that unresolved violations “may result in legal action without further notice, including, without limitation, seizure and injunction” [7].
• March 3, 2026: 30 warning letters to telehealth companies. FDA cited “claims implying sameness with FDA-approved products and obscuring product sourcing by advertising drug products branded with the telehealth firm’s name or trademark without qualification, implying they are the compounder” [4].
• June 15-16, 2026: 25 more telehealth warning letters, plus a dedicated FDA compliance page for telehealth marketers [5][12].
• August 2026: a batch of unapproved new drug and misbranding letters to peptide sellers marketing products “for research purposes” or “not for human consumption” [1].

States have moved too. Ohio’s July 2025 pharmacy board guidance treats semaglutide and tirzepatide as no longer compoundable copies and bans retatrutide and cagrilintide. Washington’s pharmacy commission issued a limited stop service order against a pharmacy license in March 2025. California’s revised compounding regulations took effect October 1, 2025 [10].

What is the 503B bulks list, and why does it matter?

Outsourcing facilities generally cannot compound from bulk drug substance unless that substance is on the FDA’s 503B bulks list or the drug is in shortage at the time. Semaglutide is on neither.

On April 30, 2026 the FDA went further and proposed to permanently exclude semaglutide, tirzepatide and liraglutide from the list, saying it “did not identify a clinical need for outsourcing facilities to compound” them from bulk. Then-FDA Commissioner Marty Makary, who resigned on May 12, 2026 and was succeeded in an acting capacity by Kyle Diamantas, framed it as protecting patients “while continuing to provide a transparent, science-based pathway for public input.” Comments were due June 29, 2026 [6]. As of September 14, 2026 the FDA had not published a final determination, so semaglutide is neither on the bulks list nor formally excluded from it.

If that exclusion is finalized, the bulk pathway closes for good outside a future declared shortage. It is the single most consequential open regulatory question in this space.

What should I ask before buying semaglutide online?

The FDA publishes its own list of telehealth red flags. Treat these as warning signs [1]:

• The company says the compounded drug is the same as an FDA-approved drug.
• Prices are deeply discounted or seem too good to be true.
• The medicine looks different from what you received before, or arrives damaged or without instructions for use.
• There is no screening and prescription by a licensed doctor before you get medicine.
• No licensed doctor is available to answer questions after you receive it.
• There are spelling errors on the label or an incorrect pharmacy address.
• The pharmacy name on the label looks questionable.

Three direct questions are worth asking any provider:

1. Is this the FDA-approved product, or a compounded preparation?
2. Which licensed pharmacy compounds it, and can you name it?
3. If it is compounded, what is the documented reason the approved product will not work for me?

A legitimate operation can answer all three without hesitation.

The bottom line

Compounded semaglutide is not FDA approved, is not a generic, and since spring 2025 is not generally lawful as a stand-in for Ozempic or Wegovy. The FDA has spent the last year building the enforcement machinery to make that stick: warning letters in the dozens, an import alert on active ingredients, and a proposal that would permanently close bulk compounding.

Meanwhile the approved market has gotten cheaper and broader, with direct-purchase programs, a pill version of Wegovy and a rebranded Ozempic tablet. If cost is what pushed you toward a compounded product, that is worth raising with your prescriber and pharmacist, because the landscape in 2026 is not what it was in 2023.

Sources

1. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
2. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
3. FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers, Wilson Sonsini
4. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
5. FDA’s Focus Returns to Compounding and Telehealth: Another Wave of Warning Letters, Sheppard Mullin
6. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
7. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs
8. Import Alert 66-80, FDA
9. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products
10. Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides, Sheppard Mullin
11. Court Backs FDA in Tirzepatide Compounding Case, McDermott+
12. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs
13. Outsourcing Facilities Association v. FDA, No. 25-10758 (5th Cir. Aug. 27, 2026)
14. Fifth Circuit Upholds FDA on GLP-1 Shortage Decisions, Clark Hill